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Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hos-
pitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic
criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan,
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were col-
lected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and
device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients.
Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), entero-
cocci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomog-
raphy/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major
criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE
(16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or
pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery
was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death
occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were
Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications,
abscess, and failure to undertake surgery when indicated.
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Conclusion Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its
clinical, microbiological, imaging, and therapeutic profiles.
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Introduction
Infective endocarditis (IE) is a severe disease that is associated with
high morbidity and mortality1–5 and whose incidence and severity re-
main unchanged (or even increased) despite improvements in diag-
nostic and therapeutic strategies. Reasons for this persistently poor
prognosis are numerous and include an increasing proportion of
older patients with more severe disease, changing epidemiological
profiles and greater numbers of patients with prosthetic valve or de-
vice-related infection.5,6
There were several motivations to create an ESC-EORP European
Endocarditis Registry:
• The epidemiological profile of IE has changed in recent decades,
with important differences between countries and increasing num-
bers of staphylococcal and nosocomial cases.1,6 While the
European Society of Cardiology (ESC) Euro Heart Survey on
valvular heart disease performed in 2001 provided useful informa-
tion regarding the management of IE across Europe at that time,7
no attempt has been made to update and implement the results
of the Euro Heart Survey in the contemporary era. There is,
therefore, a need for a comprehensive and dedicated IE survey.
• New strategies have been developed to improve diagnosis and
prognosis. The ESC Guidelines on the management of IE were
published in 2015 and provided new insights into the diagnostic
and therapeutic management of these patients.8 However, their
implementation in real-world clinical practice has never been
studied.
• Although echocardiography is the principal diagnostic imaging
technique used in IE9, other non-invasive imaging techniques have
received increasing attention, including multislice computed tom-
ography (MSCT), magnetic resonance imaging, and nuclear imaging
(18F-fluorodeoxyglucose positron emission tomography/computed
tomography, and leucocyte scintigraphy).10–12 However, their
availability and application in different countries are unknown.
• Early surgery is recommended in patients with complicated IE but
its impact on prognosis is still debated.13–15 With the present IE
registry, it will be possible to assess whether the implementation
of guidelines and increased use of early surgery are associated
with a reduced in-hospital and 1-year mortality.
The aim of the ESC-EORP European Endocarditis Registry
(EURO-ENDO) is to undertake a contemporary international inves-
tigation of the care and outcomes of IE in Europe. The primary ob-
jective is to evaluate the outcome of patients diagnosed with IE. The
secondary objectives are to assess the current clinical, epidemiologic-
al, microbiological, therapeutic, and prognostic characteristics of IE in
Europe, to assess the current practices of imaging in IE in Europe and
in affiliated countries, to assess the degree of implementation of the
ESC guidelines in practice, and to compare these current data with
those obtained in the Euro Heart Survey. The additional input of sev-
eral non-European countries which accepted to participate in the
registry will also enable comparison of IE in Europe and other inter-
national regions.
Methods
Study design and data collection
The ESC-EORP EURO-ENDO registry is a prospective multicentre ob-
servational study of patients presenting with definite or possible IE to hos-
pitals in Europe and ESC-affiliated/non-affiliated countries. The detailed
methodology of EURO-ENDO has already been reported.16 Briefly,
from 1 January 2016 to 31 March 2018, centres were asked to include
consecutive patients aged greater than 18 years who presented with IE
during a 1-year period. Participating centres were identified by the
European Association of Cardiovascular Imaging as either high level IE
centres: high volume of treated patients (>_20 patients per year) with ex-
pertise in IE diagnosis, management, imaging and surgical therapy or low-
volume centres (<20 patients per year), without surgical facilities16.
Inclusion criteria were a diagnosis of definite IE (or possible IE considered
and treated as IE) based on the ESC 2015 IE diagnostic criteria.8 After
informed consent, data were collected at inclusion and during hospitaliza-
tion, including demographics, patient history, Charlson index, taking into
account age and several comorbidities,17 clinical, biological, microbio-
logical, and echocardiographic findings, use of other imaging techniques
(CT scan, 18F-FDG PET/CT, leucocyte scintigraphy), medical therapy,
complications (embolic event, infectious, and haemodynamic complica-
tions), theoretical indications for surgery, and in-hospital mortality.16
Data management and statistical analysis
All data were collected by the collecting officers or investigators at the
participating centres and included in an electronic case report form
(CRF) for on-line data entry. All patients enrolled with possible or definite
IE were included in the analyses. Univariable analysis was applied to both
continuous and categorical variables. Continuous variables were
reported as mean ± SD or as median and interquartile range (IQR).
Among-group comparisons were made using a non-parametric test
(Kruskal–Wallis test). Categorical variables were reported as counts and
percentages. Among-group 2 2 comparisons were made using a v2 test
or Fisher’s exact test if any expected cell count was <5. In other cases,
the Monte-Carlo estimate of the exact P-value was used. Plots of the
Kaplan–Meier curves for time to all causes of deaths were performed.
The Kaplan–Meier curve of time to death were also adjusted for the
covariates from the Cox proportional hazard model.
Pairwise correlations between all candidate variables (variables with
P < 0.10 in univariate) within the model and variables considered of rele-
vant clinical interest were tested before proceeding to the multivariable
model. In case of correlation, some criteria were not taken into account.
A backward multivariable Cox regression analysis was performed to
identify the independent predictors of in-hospital all-cause mortality































































































(only the first month of survival was taken into account). Significance lev-
els of 0.05 were required to allow a variable to stay (SLSTAY = 0.05)
within the model. Some measures of model fit were considered: con-
cordance and the Goodness of fit test proposed by May and Hosmer.18
In addition, the proportional hazard ratios assumptions were verified
graphically and with the Schoenfeld residuals test. A backward multivari-
able logistic regression analysis was performed to identify the independ-
ent predictors of indication of cardiac surgery. Significance levels of 0.05
were required to allow a variable to stay within the model. All analyses
were performed using SAS statistical software version 9.4 (SAS Institute,
Inc., Cary, NC, USA) and R version 3.5.1.
Results
A total of 156 centres from 40 countries included 3116 cases of IE
(Supplementary material online, Table S1), representing a mean of
20.19 patients per centre per year. Among the 156 active centres,
120 (76.9%) were from ESC-affiliated countries and 36 (23.1%) were
outside Europe, including 79.5% high-volume centres and 20.5% low-
volume centres16. Low-volume centres included 238 (7.6%) patients,
high-volume centres 2878 (92.4%) patients, without difference be-
tween European and non-European countries. Patients were
enrolled from the cardiology ward in 48.9% of cases, the ICC/CCU in
15.0%, the general internal medicine ward in 8.8%, the echocardiog-
raphy laboratory in 7.8%, the cardiac surgical ward in 10.1%, the infec-
tious diseases ward in 9.3%, and the electrophysiology ward in 0.1%.
Infective endocarditis was definite in 2610 (83.8%) patients and pos-
sible in 506 (16.2%).
Patient demographics and characteristics
The main demographic and characteristics of patients are displayed in
Table 1. Among the 3116 patients, 1764 (56.6%) had native valve IE
(NVE), 939 (30.1%) prosthetic IE (PVIE), and 308 (9.9%) intracardiac
device-related IE (CDRIE), with similar proportions observed within
and outside Europe. Infective endocarditis complicated congenital
heart disease in 365 (11.7%) patients. The 105 remaining patients not
categorized as PVIE, NVE, or CDRIE corresponded either to another
location or to an undetermined location of the infective process.
These patients were included in total analysis but not in groups com-
parisons analysis. Mean age was 59.25 ± 18.03 years (46.3% >_
65 years and 12.0% >_ 80 years) and was higher in European than in
non-European countries (60.97± 17.36 vs. 52.66 ± 19.01,
P < 0.0001). There was a history of intravenous drug use in 212
(6.9%) patients. Infective endocarditis was healthcare associated in
1027 (32.96%) patients (nosocomial in 60.8% of them, non-
nosocomial in 39.2%), community-acquired in 2046 (65.66%)
patients, and undetermined in 1.38% of patients, without significant
difference between European and non-European countries.
The most frequent preceding non-cardiac interventions per-
formed within the last 6 months were dental procedure (7.9%),
gastrointestinal intervention (3.4%), colonoscopy (3.3%), and uro-
genital intervention (2.8%). The portal of entry was dental in 9.8%, di-
gestive in 6.3%, and genitourinary in 4.5%. The location of IE was
aortic in 49.5% patients, mitral in 42.0%, tricuspid in 11.4%, and pul-
monary in 2.4%. Infective endocarditis affected two or more valves in
556 (18.2%) patients. The median time since first medical




The main clinical and biological characteristics of patients are dis-
played in Supplementary material online, Tables S2 and S3. Fever
(77.7%) and congestive heart failure (27.2%) were the most frequent
symptoms. Symptomatic embolic events were present on admission
in 25.3% of patients. Conduction abnormalities were observed on ad-
mission in 11.5% of cases, including first-degree AV block in 8.1% of
cases, and third-degree AV block in 2.8%. New AV block under ther-
apy occurred in 4.6% of cases. Blood cultures were positive for IE in
2461/3116 (79.0%) patients. The most frequent microorganisms
identified were staphylococci in 1085 (44.1%) patients, oral strepto-
cocci in 304 (12.4%), enterococci in 390 (15.8%), and Streptococcus
gallolyticus in 162 (6.6%). Coxiella burnetii IE was observed in 26
(0.8%) patients. The only difference between European and non-
European countries was a higher frequency of Methi-S Staphylococcus
aureus in European countries (25.7 vs. 17.7%, P = 0.0002).
Imaging
Among the 3116 patients, echocardiography was performed in 3111
(99.8%), transthoracic echocardiography (TTE) in 2793 (89.8%), and
transoesophageal echocardiography (TOE) in 1808 (58.1%), with
TOE being more frequently used in suspected PVIE (P < 0.0001). 18F-
fluorodeoxyglucose positron emission tomography/computed tom-
ography was performed in 518 (16.6%), leucocyte scintigraphy in 38
(1.2%), and multislice CT in 1656 (53.1%) patients (Figure 1). 18F-fluo-
rodeoxyglucose positron emission tomography/computed tomog-
raphy was more frequently used in PVIE (25.0%) and CDRIE (26.0%)
than in NVE (9.5%) (P < 0.0001).
Use of different imaging techniques differed between countries
(Supplementary material online, Table S4). For instance, although
echocardiography was used similarly between countries, 18F-FDG
PET CT was more frequently used in Western Europe (33.9%), but
very rarely in South America (2.1%), North Africa (0%), and Asia (0.5
to 8.5%).
A major imaging criterion was found by echocardiography in 2776
(89.1%) patients, including vegetation in 72.7% of patients, abscess or
false aneurysm in 13.9%, and new prosthetic dehiscence in 3.4%.
Abscesses were more frequently observed in PVIE than in other
forms of IE (Figure 2).
Positron emission tomography/computed tomography equipment
was available in 71 (70.3%) centres in ESC-affiliated countries and in
18 (56.3%) centres elsewhere and was ultimately used in 16.6% of
patients (25.0% in suspected PVIE). 18F-fluorodeoxyglucose positron
emission tomography/computed tomography was performed at a
mean of 8 (IQR 4.0–15.0) days after inclusion, including 46.7% during
the first week, 27.2% during the second week, and 26.1% thereafter.
18F-fluorodeoxyglucose positron emission tomography/computed
tomography presented with any positivity in 361 (69.7%) patients,
74.9% in PVIE, 62.5% in NVE, and 77.5% in CDRIE (P = 0.018).
Considering only cardiac uptake (major criterion), 18F-FDG PET/CT
was positive in 222 (42.9%) patients, with a better sensitivity in PVIE
(66.8%) than in NVE (28.0%) and CDRIE (16.3%). Extra-cardiac
























..uptake was observed in 201 (38.8%) patients, including 34.5% in PVIE,
42.3% in NVE, and 43.8% in CDRIE, respectively, the most frequent
uptake being in the liver in 5.0% of cases, lung in 27.1%, spleen in
19.6%, spine in 21.8%, and bowel in 18.9%.
Cardiac CT was performed in 300 (9.6%) patients, including 11.4%
of PVIE, 9.9% of NVE, and 4.2% of CDRIE. Valvular lesions were
observed in 179 (59.7%) patients, 52 (48.6%) of PVIE, and 119
(68.4%) of NVE (P = 0.01). Perivalvular extension was observed in
101 (33.7%) patients, in 53 (49.5%) of PVIE, and 45 (25.9%) of NVE
(P < 0.0001). Extra-cardiac CT was performed in 1656 patients and
revealed extra-cardiac lesions in 798 (48.2%).
No positive imaging criterion was observed in only 280/3116
(9.0%) patients.
In-hospital follow-up under treatment
Main events occurring during hospitalization are summarized in
Supplementary material online, Table S5.
Embolic events were the most frequent complication, observed in
20.6% of patients, followed by acute renal failure (17.7%) and heart
failure (14.1%). Embolic events under therapy were more frequent in
patients with definite (22.7%) than in patients with possible (9.5%) IE
(P < 0.0001) and was similar between European and non-European
....................................................................................................................................................................................................................
Table 1 Patient demographics and clinical characteristics
Total (n 5 3116) Prosthesis1Repair
(n 5 939)
Native (n 5 1764) PM/ICD (n 5 308) P-value
Demography
Age (years)
N 3116 939 1764 308
Mean ± SD 59.25 ± 18.03 63.36 ± 16.81 55.61 ± 18.45 66.77 ± 14.11 <0.0001
Median (IQR) 63.0 (46.0–73.0) 67.0 (54.0–75.0) 58.0 (41.0–70.0) 69.0 (60.0–76.0) <0.0001
Age >_ 65 years 1443/3116 (46.3%) 538/939 (57.3%) 662/1764 (37.5%) 194/308 (63.0%) <0.0001
Age >_ 80 years 375/3116 (12.0%) 141/939 (15.0%) 163/1764 (9.2%) 56/308 (18.2%) <0.0001
Females (%) 969/3116 (31.1%) 292/939 (31.1%) 553/1764 (31.3%) 86/308 (27.9%) 0.4901
History of cardiovascular diseases
Heart failure 662/2840 (23.3%) 271/856 (31.7%) 238/1620 (14.7%) 123/270 (45.6%) <0.0001
Congenital disease 365/3114 (11.7%) 130/938 (13.9%) 197/1763 (11.2%) 18/308 (5.8%) 0.0001
Ischaemic heart disease 622/2897 (21.5%) 266/881 (30.2%) 207/1637 (12.6%) 128/284 (45.1%) <0.0001
Atrial fibrillation 767/2918 (26.3%) 365/891 (41.0%) 240/1634 (14.7%) 133/294 (45.2%) <0.0001
Hypertrophic cardiomyopathy 63/2840 (2.2%) 20/856 (2.3%) 28/1620 (1.7%) 11/270 (4.1%) 0.0498
Known valve murmur 972/2840 (34.2%) 455/856 (53.2%) 427/1620 (26.4%) 55/270 (20.4%) <0.0001
Previous endocarditis (%) 274/3116 (8.8%) 170/939 (18.1%) 67/1764 (3.8%) 17/308 (5.5%) <0.0001
Device therapy
Pacemaker 325/3116 (10.4%) 97/939 (10.3%) 53/1764 (3.0%) 161/308 (52.3%)
ICD (defibrillator) 125/3116 (4.0%) 18/939 (1.9%) 15/1764 (0.9%) 89/308 (28.9%)
CRT-D (with ICD) 72/3116 (2.3%) 13/939 (1.4%) 3/1764 (0.2%) 47/308 (15.3%)
CRT-P (pacing only) 15/3116 (0.5%) 7/939 (0.7%) 1/1764 (0.1%) 6/308 (1.9%)
Risk factors
Previous stroke/TIA 340/2860 (11.9%) 132/867 (15.2%) 160/1626 (9.8%) 34/273 (12.5%) 0.0003
Arterial hypertension 1502/3111 (48.3%) 531/938 (56.6%) 726/1762 (41.2%) 194/306 (63.4%) <0.0001
COPD/asthma 318/3111 (10.2%) 98/937 (10.5%) 160/1762 (9.1%) 49/307 (16.0%) 0.0011
Chronic renal failure 553/3113 (17.8%) 191/938 (20.4%) 255/1762 (14.5%) 83/308 (26.9%) <0.0001
Dialysis 163/3113 (5.2%) 28/938 (3.0%) 107/1762 (6.1%) 18/308 (5.8%) <0.0001
HIV 31/3038 (1.0%) 3/916 (0.3%) 24/1726 (1.4%) 2/294 (0.7%) 0.0212
Hypo/hyperthyroidism 226/2820 (8.0%) 93/852 (10.9%) 98/1606 (6.1%) 24/270 (8.9%) <0.0001
Chronic autoimmune disease 109/3103 (3.5%) 18/937 (1.9%) 74/1753 (4.2%) 12/308 (3.9%) 0.0030
Cancer 361/3088 (11.7%) 107/930 (11.5%) 210/1746 (12.0%) 31/308 (10.1%) 0.6230
Current pregnancy 8/3092 (0.3%) 2/932 (0.2%) 6/1749 (0.3%) 0/307 (0.0%) 0.7716
Smoking 759/2938 (25.8%) 166/880 (18.9%) 507/1666 (30.4%) 68/296 (23.0%) <0.0001
Intravenous drug dependency 212/3067 (6.9%) 20/930 (2.2%) 184/1729 (10.6%) 3/305 (1.0%) <0.0001
Alcohol abuse 228/3003 (7.6%) 44/910 (4.8%) 166/1691 (9.8%) 12/301 (4.0%) <0.0001
Immunosuppressive treatment 104/2840 (3.7%) 21/856 (2.5%) 71/1620 (4.4%) 8/270 (3.0%) 0.0450
Long corticotherapy 127/2840 (4.5%) 28/856 (3.3%) 84/1620 (5.2%) 13/270 (4.8%) 0.0871
Intravenous catheter 250/3104 (8.1%) 63/934 (6.7%) 150/1760 (8.5%) 24/306 (7.8%) 0.2672
COPD, chronic obstructive pulmonary disease; ICD, intracardiac defibrillator; PM, pacemaker; TIA: transient ischaemic attack.

























..countries (21.1% vs. 18.4%, P = ns). Factors associated with new em-
bolic events under therapy by univariate analysis are age, previous
pulmonary embolism, heart failure, statins, previous VKA therapy,
aortic, tricuspid IE or CDRIE, pulmonary endocarditis, intracardiac
defibrillator (ICD)/pacemaker (PM) endocarditis, vegetation pres-
ence and size, positive blood cultures, other germs, and S. aureus in-
fection. No relationship was observed between this time delay and
the risk of embolism (P = ns). By multivariable analysis, tricuspid (OR
= 1.78, 95% CI [1.38–2.29], P < 0.0001) or pulmonary (OR =2.31,
95% CI [1.42–3.74], P = 0.0007) or ICD/PM (OR = 0.61, 95% CI
[0.44–0.84], P = 0.0028) endocarditis, presence of a vegetation (OR
= 1.31, 95% CI [1.06–1.62], P = 0.0138), Methi-S S. aureus
endocarditis (OR =1.41, 95% CI [1.13–1.75], P = 0.0024) and Methi-R
S. aureus endocarditis (OR =1.77, 95% CI [1.26–2.50], P = 0.0011)
were independently associated with new embolic events under
therapy.
Surgery was performed during hospitalization in 1596 (51.2%)
patients. Following ESC guidelines, theoretical indication for cardiac
surgery was present in 2160 (69.3%) patients. Among them, surgery
was finally performed in 46.1% of PVIE, 53.7% of NVE, and surgical or
percutaneous extraction in 65.3% of CDRIE. Surgery was performed
on an emergency basis in 6.7% of operated patients, urgently in
24.8%, beyond the 1st week in 32%, and as an elective procedure in
36.5%. Cardiac surgery was less frequently performed in possible
Figure 1 Imaging studies performed in the overall population and three subgroups. MSCT, multislice computed tomography; PET-CT, 18F-fluoro-
deoxyglucose positron emission tomography/computed tomography; TOE, transoesophageal echocardiography; TTE, transthoracic
echocardiography.
Figure 2 Frequency of major echocardiographic criteria observed in the overall population and three subgroups.
















































..(64.7%) than in definite (75.3%) IE (P < 0.0001). Indications for sur-
gery were haemodynamic in 46.3% of cases, embolic in 32.1%, and in-
fectious in 64.2%. Among factors associated with more frequent
cardiac surgery by multivariable analysis, the most powerful were
congestive heart failure (OR = 2.27 [1.57–3.28], P < 0.0001), vegeta-
tion length > 15 mm (OR = 2.33 [1.75–3.10], P < 0.0001), cerebral
complication (OR= 1.69 [1.13–2.53], P = 0.0105), abscess (OR =
4.18 [2.59–6.76], P < 0.0001), and management in an European coun-
try (OR 1.45 [1.15–1.82], P = 0.0016). Conversely, high Charlson
index (OR =0.94 [0.91–0.97], P = 0.0005), and female gender (OR
=0.73 [0.59–0.90], P = 0.0028) were associated with lower surgical
use.
Reasons for absence of surgery when indicated and types of sur-
gery performed are summarized in Supplementary material online,
Table S6. Comparison of the reasons for absence of surgery when
indicated between European and non-European countries found
more frequent patient refusal (30.4% vs. 16.5%, P = 0.0018) and more
frequent neurological complication (17.4% vs. 10.0%, P = 0.038) in
non-European countries.
In-hospital death occurred in 532 (17.1%) patients and was higher in
PVIE than in other groups (Table 2) but was similar between
European and non-European countries (16.8% vs. 18.1%, P = ns).
Causes of in-hospital death are reported in Table 2. By univariate Cox
regression analysis (Table 3), type of endocarditis, age, Charlson
index, creatinine > 2 mg/dL, congestive heart failure, S. aureus infec-
tion, vegetation length, cerebral complications, nosocomial source of
infection, and perivalvular complications were significantly associated
with in-hospital mortality. Predictors of mortality by multivariable
analysis (Table 4) were Charlson index, creatinine > 2 mg/dL, con-
gestive heart failure, vegetation length > 10 mm, cerebral complica-
tions, abscess, and failure to undertake surgery despite a guideline
recommended indication. In-hospital mortality was not significantly
different between NVE, PVIE, and CDRIE (Figure 3A) but was higher
in patients in whom surgery was indicated but not performed (Figure
3B). Similar results were obtained when the Kaplan–Meier curve of
time to death were adjusted for the covariates from the Cox propor-
tional hazard model (Take home figure).
Discussion
The EURO-ENDO registry provides a unique opportunity to assess
the current characteristics of IE in Europe, including clinical presenta-
tion, microbiology, complications, management, and prognosis. Since
several countries beyond Europe also participated, it will also enable
comparison of the characteristics of IE according to geographical and
socioeconomic factors. Finally, although 20 times larger, it will allow
historical comparison with the previous EuroHeart survey7 which
enrolled patients over a 4-month period in 2001.
The following main messages arise from the analysis of EURO
ENDO:
(1) IE more frequently affects men around 60 years of age.
(2) PVIE, CDRIE, nosocomial, staphylococcal, and enterococcal endo-
carditis are more frequent.
....................................................................................................................................................................................................................
Table 2 In-hospital mortality
Total (n 5 3116) Prosthesis1Repair
(n 5 939)
Native (n 51764) PM/ICD (n 5 308) P-value
Death 532/3116 (17.1%) 187/939 (19.9%) 286/1764 (16.2%) 47/308 (15.3%) 0.038
Cause of death
Cardiovascular 151/531 (28.4%) 65/186 (34.9%) 76/286 (26.6%) 8/47 (17.0%)
Non-cardiovascular 156/531 (29.4%) 47/186 (25.3%) 85/286 (29.7%) 18/47 (38.3%)
Cardiovascular þ non-cardiovascular 194/531 (36.5%) 60/186 (32.3%) 110/286 (38.5%) 21/47 (44.7%)
Unknown 30/531 (5.6%) 14/186 (7.5%) 15/286 (5.2%) 0/47 (0.0%)
If cardiovascular
Heart failure 245/345 (71.0%) 94/125 (75.2%) 133/186 (71.5%) 16/29 (55.2%)
Arrhythmia 42/345 (12.2%) 9/125 (7.2%) 23/186 (12.4%) 9/29 (31.0%)
Cardiac perforation/tamponade 11/345 (3.2%) 1/125 (0.8%) 9/186 (4.8%) 1/29 (3.4%)
Acute MI 8/345 (2.3%) 5/125 (4.0%) 3/186 (1.6%) 0/29 (0.0%)
Cerebral embolism 41/345 (11.9%) 11/125 (8.8%) 26/186 (14.0%) 1/29 (3.4%)
Pulmonary embolism 13/345 (3.8%) 3/125 (2.4%) 8/186 (4.3%) 2/29 (6.9%)
Peripheral embolism 3/345 (0.9%) 0/125 (0.0%) 3/186 (1.6%) 0/29 (0.0%)
Other cardiovascular 40/345 (11.6%) 16/125 (12.8%) 22/186 (11.8%) 2/29 (6.9%)
If non-cardiovascular
Neoplasia 12/350 (3.4%) 2/107 (1.9%) 8/195 (4.1%) 1/39 (2.6%)
Sepsis 269/350 (76.9%) 80/107 (74.8%) 152/195 (77.9%) 31/39 (79.5%)
Other 70/350 (20.0%) 26/107 (24.3%) 37/195 (19.0%) 4/39 (10.3%)
If surgery performed
Post-cardiac surgery 170/532 (32.0%) 74/187 (39.6%) 79/286 (27.6%) 16/47 (34.0%)
Post-non-cardiac surgery 16/532 (3.0%) 1/187 (0.5%) 6/286 (2.1%) 9/47 (19.1%)
ICD, intracardiac defibrillator; PM, pacemaker.























(3) Oral streptococcal endocarditis is less frequent, and its frequency
has not increased since implementation of the 2009 and 2015 rec-
ommendations restricting indications for antibiotic prophylaxis.
(4) New imaging techniques (18F-FDG PET/CT) have emerged and are
used in several countries worldwide.
(5) Mechanical valve replacement is decreasing, and mitral valve repair
is still underused in IE.
(6) The prognosis of IE is still unacceptably poor and more aggressive
management of this deadly disease remains necessary.
Current clinical and microbiological
characteristics of IE
EURO-ENDO confirms the increasing age of the population with IE.
This in agreement with the progressive increase in age observed in
three 1-year population-based surveys conducted in 1991, 1999, and
2008 in three French regions,5,6 in which total IE incidence remained
stable over time, but mean age progressively increased from
57.9± 16.6 years in 1991 to 61.6± 16.3 years in 2008.
The frequency of prosthetic IE is also increasing, accounting for
30% of cases in EURO-ENDO. In comparison, PVIE represented only
26% of cases in the EuroHeart survey,7 25% in the 2008 French regis-
try,5 and 21% in the International Collaboration on Endocarditis-
Prospective Cohort Study reported in 2009.1 In this latter series, the
frequency of CDRIE was also much lower (7% of IE) than in the
EURO-ENDO registry, confirming the increasing proportion of both
PVIE and CDRIE as compared with NVE.
The low frequency of dental portal of entry in EUROENDO, com-
bined with the low frequency of oral streptococci [lower than in the
EuroHeart Survey (15%),7 the 2008 French registry (20.6%),5 and the
International Collaboration on Endocarditis-Prospective Cohort
Study (17%)1], is reassuring in the wake of the 2009 and 2015 ESC
guidelines, which recommended restricting the use of antibiotic
prophylaxis to high risk populations undergoing at-risk dental proce-
dures.8 Conversely, the high frequency of enterococci observed in
EURO-ENDO represents a significant change compared with the 8%
and 10% frequency observed in the 2002 French survey5 and 2009
International Collaboration on Endocarditis-Prospective Cohort
Study,1 respectively. The burden of enterococcal IE may relate to
increasing age.19 Finally, the number of culture-negative IE observed
in EURO-ENDO (21%) was higher than those previously reported
....................................................................................................................................................................................................................
Table 3 Univariate Cox regression analysis for all causes of death at discharge (1-month period)
Effect* Hazard ratio 95% CI P-value*
Type of endocarditis PM/ICD 0.80 0.53–1.20 0.08
ProsthesisþRepair 1.21 0.97–1.52
Age (per 10 years) 1.10 1.04–1.18 0.002
Gender Female 1.15 0.92–1.44 0.216
Charlson index 1.14 1.11–1.17 <0.0001
Creatinine >2 mg/dL 2.53 2.01–3.19 <0.0001
Staphylococcus aureus 1.36 1.04–1.74 0.008
Congestive heart failure 2.90 2.31–3.64 <0.0001
Vegetation length > 10 mm 2.44 1.93–3.08 <0.0001
Cerebral complication 2.62 2.02–3.41 <0.0001
Abscess 1.71 1.29–2.27 0.0002
ESC countries 1.12 0.86–1.46 0.42
Source of infection Non-nosocomial 1.35 0.95–1.93 0.0007
Nosocomial 1.68 1.27–2.21
Indication—surgery performed Indication—not performed 4.02 3.06–5.27 <0.0001
Indication—performed 0.72 0.54–0.97
Type of centres High-volume centres 1.13 0.74–1.71 0.57
Transferred from another hospital 0.75 0.60–0.95 0.02
*P-value corresponds to the results of Wald test. For Region: the reference is North America; For type of endocarditis: Native; For indication—Surgery performed: No indica-
tion; For countries: Non-ESC; For type of centres: Low level IE; For source of infection: Community.
ICD, intracardiac defibrillator; PM, pacemaker.
.................................................................................................
Table 4 Multivariable Cox regression analysis for all




Charlson index 1.07 [1.04–1.11] <0.0001
Creatinine >2 mg/dL 1.58 [1.19–2.11] <0.0017
Congestive heart failure 2.09 [1.58–2.77] <0.0001
Vegetation length > 10 mm 2.12 [1.64–2.73] <0.0001
Cerebral complication 2.21 [1.61–3.04] <0.0001
Abscess 1.50 [1.07–2.10] 0.0186
Indication—surgery not performed 2.84 [2.00–4.03] <0.001
Indication—surgery performed 0.63 [0.43–0.92] 0.0169
Goodness of fit test: P = 0.18. Concordance = 0.77—Global Schoenfeld residual
test P = 0.12.
*P-value corresponds to the results of Wald test. For indication—surgery per-
formed or not, the reference is no indication.






























[14% and 11% frequency observed in the 2002 French survey5 and
2009 International Collaboration on Endocarditis-Prospective
Cohort Study1].
Imaging
EURO-ENDO reveals a transformation in the use of imaging techni-
ques since publication of the 2015 ESC guidelines.8 Echocardiography
remains the most frequently used technique. Although the respective
diagnostic values of TTE and TOE were not compared in EURO-
ENDO, the observed more frequent use of TOE in suspected PVIE is
in agreement with current guidelines for the use of echocardiography
in IE.9 Surprisingly, TOE was performed in only 58.1% of patients,
which may be considered a low proportion compared with current
guidelines.8 However, a wide range of TOE use was observed among
countries and regions (Supplementary material online, Table S4).
18F-fluorodeoxyglucose positron emission tomography/computed
tomography and multislice CT are more frequently used, particularly
in the field of suspected PVIE. Interestingly, there was an important
gap in EURO-ENDO between the high availability of PET/CT and its
relatively limited use in clinical practice. This underuse might have
several explanations, but the most important are probably the vari-
able availability of PET/CT for cardiac studies, the technique being
preferentially used for the follow-up of patients with cancer in many
centres, and its limitations in haemodynamically unstable
patients.8,10–12
18F-fluorodeoxyglucose positron emission tomography/computed
tomography has recently been found to be useful for the diagnosis of
Figure 3 (A) The Kaplan–Meier curves for all-cause mortality according to type of endocarditis. (B) Cumulative survival in three subgroups accord-
ing to the presence or absence of an indication of surgery and whether surgery was performed or not.



















































..prosthetic valve IE,10–12 supporting the implementation of abnormal
FDG uptake as a novel major criterion for IE in the 2015 ESC guidelines,8
despite inherent limitations.20 In EURO-ENDO, 18F-FDG PET/CT
demonstrated high sensitivity in PVIE (63%) compared with NVE (28%)
and CDRIE (16.2%). This confirms that 18F-FDG PET/CT should be used
in suspected PVIE (particularly when the diagnosis is uncertain) and that
additional studies are needed to define the best indications for this
test in NVE and CDRIE. The additional diagnostic value of 18F-FDG
PET/CT and cardiac CT in suspected PVIE validates use of the ESC
criteria rather than the Duke criteria21 in this setting.
Although MSCT was used in more than half of patients in EURO-
ENDO, cardiac CT was performed in only 10%, demonstrating clear
underuse of this technique, particularly for the diagnosis of perivalvu-
lar involvement in PVIE.8,11
Management and outcome of infective
endocarditis in EUROENDO registry
Use of surgery during hospitalization in EURO-ENDO was similar to
the patterns observed in the Euro Heart Survey,7 2008 French
Registry,5 and 2009 International Collaboration on Endocarditis-
Prospective Cohort Study.1 Approximately 50% of patients with IE
underwent surgery during hospitalization (both in NVE and PVIE)
and the principal indications for surgery were haemodynamic, embol-
ic, and infectious. Surprisingly the most frequent indication in EURO-
ENDO was infectious, probably related to the high proportion of
PVIE and perivalvular lesions. Other important observations related
to the choice of surgical technique. Bioprosthetic aortic valves were
used in most cases (58.3%) in EURO-ENDO whereas mechanical
valves were preferred at the time of the EuroHeart Survey (74%). In
contrast, the application of mitral valve repair techniques was rela-
tively disappointing (25.1%) in EURO-ENDO and similar to that
reported in the Euro Heart Survey. One explanation is that significant
delay before surgery in EURO-ENDO resulted in valve destruction
and difficulty in performing valve repair.11 Indeed, one of the key rea-
sons for withholding appropriate surgery in EURO-ENDO was death
before surgery could be performed (22.5% of cases). This unaccept-
able feature underlines the need for early discussion with surgeons
within the IE team, as recommended by ESC guidelines.8
EURO-ENDO confirms the high risk of embolic events in IE. Embolic
events occur in up to 40% of patients with IE (with a high burden of
cerebral manifestations22,23) and are associated with increased mor-
bidity and mortality.23 The risk of new embolic events (i.e. after initi-
ation of antibiotic therapy) is only 6–21%,21 yet embolism was
already present on admission in 25.2% patients in the EURO-ENDO
registry and the rate of new embolic events occurring during hospi-
talization was very high (20.5%). In comparison, embolic events were
observed in 23% in the ICE cohort,1 and embolism was the reason
for surgery in 18% of the Euro Heart survey.7 Factors associated with
embolic events were similar to previous studies, with a major role of
staphylococcal infection, vegetation presence, and size. More surpris-
ing was the fact that tricuspid, pulmonary, and aortic IE were associ-
ated with the highest risk of embolism.
In-hospital mortality rate is associated with known risk factors,
including PVIE, age, comorbidity, S. aureus infection, congestive heart
failure, cerebral complications, perivalvular lesions, and vegetation
length. The major cause of death was heart failure. Interestingly, mor-
tality was particularly high in EURO-ENDO when surgery was
Take home figure Prognosis of infective endocarditis is dismal when cardiac surgery is indicated but not performed (adjusted Kaplan–Meier
curve).































































































indicated but not performed, emphasizing the role of an aggressive
surgical strategy in these patients. Although the exact reason to
contra-indicate surgery in 58.2% of patients with a theoretical surgical
indication is unknown, it is probably related to a combination of sev-
eral parameters (age, frailty, left ventricular dysfunction, and multiple
surgeries).
The 17.1% mortality observed in EURO-ENDO is consistent with
the 18% mortality observed in the ICE cohort1 but higher than the
12.6% mortality observed in the Euro Heart survey7 (although this
latter series included only 159 patients).
Study limitations
EURO-ENDO represents a unique evaluation of the current features
and treatment of IE.
Nevertheless, the study has inherent limitations and is unlikely to
be a true population-based sample. For instance, we cannot be sure
that all centres really included all their patients consecutively and pro-
spectively, since the study was based on the volunteer participation
of each centre. Like other voluntary registries, it is an observational
study of patients from centres with a special interest in IE, most
centres being tertiary referral centres with cardiac surgical pro-
grammes. These limitations were counterbalanced by the high num-
ber of enrolled patients, the quality of CRF completion, and
representation of a wide range of both university and non-academic
hospitals in many countries around the world. Another limitation of
the EURO-ENDO registry is that information concerning the num-
ber of patients transferred from the centres without cardiac surgery
to centres with cardiac surgery was missing, as well as the number of
centres having an ‘endocarditis team’.8 Both might have influenced
the outcome of the patients but could not be included in the multi-
variate analysis of predictors of death, since they were not collected
in the CRF. Finally, long-term follow-up, including events occurring
during the first year will be assessed in future ancillary studies of
EURO-ENDO.
Summary and conclusion
The ESC EORP EURO-ENDO registry is the most comprehensive
observational cohort of patients hospitalized with IE. Its main findings
are the high frequency of PVIE, CDRIE, nosocomial, staphylococcal
and enterococcal IE, the low frequency of streptococcal IE, the emer-
gence of new imaging techniques, and the persistently high in-hospital
mortality.
Although the result of EURO-ENDO should be considered with
caution, since important limitations are inherent to such a registry, it
provides new insights concerning the contemporary profile of
patients admitted to hospital with IE, their investigation, treatment
and clinical outcomes, and the influence of the 2015 ESC Clinical
Practice Guidelines for the management of IE on clinical practice.
Given the paucity of randomized or large-scale observational data in
IE, this registry offers a unique perspective on the current care and
clinical outcomes of patients with IE across a wide range of countries.
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